Did a Permissive Scientific Culture Encourage the ‘CRISPR babies’ experiment?
By Donna Dickenson, Marcy Darnovsky,
Nature Biotechnology
| 03. 15. 2019
To the Editor — The claim last November by He Jiankui to have engineered the first CRISPR-edited babies has ignited voluble condemnation from scientists worldwide. What, then, made this rogue researcher think that his ‘achievement’ would be welcomed? One possible factor is that He claimed that he was influenced by the words and actions of key US and UK scientists. He attended and was an invited speaker at several meetings about gene editing, including several focused on the ethical acceptability of human germline modification1. And he explicitly cited the 2017 US National Academies of Science report as support for what he did2.
The Nuffield Council on Bioethics in the UK also issued a report in July 20183. Notably, it concludes that germline genome editing could be permissible under certain circumstances. More strongly, it moves beyond the merely permissible to the ethically obligatory, saying in its final section (paragraph 5.2) that “there are moral reasons to continue with the present lines of research and to secure the conditions under which heritable genome editing would be...
Related Articles
By David Jensen, The California Stem Cell Report | 03.26.2026
SACRAMENTO, Ca. -- California’s $12 billion stem cell and gene therapy program scored a historic first today, announcing that it had for the first time helped to finance a revolutionary treatment that will now be available to the general public...
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
By Darren Incorvaia, Fierce Biotech | 03.11.2026
A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way for the next generation of gene editing medicines.
The approach, which is described in a Nature paper...